Remove Hormones Remove Marketing Remove Radiology
article thumbnail

Scrutinizing the West Syndrome Market Space from Growth Perspectives

Delveinsight

It can be due to the previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or on the basis of etiology that is characterized by a lack of previous signs of brain damage. The West syndrome market has different forms of ACTH available for infantile spasms.

article thumbnail

Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks

Worldwide Clinical Trials

Hormonal Status : A body’s hormones, such as levels of reproductive hormones and thyroid function, can impact tissue responses to radiation therapy. Similar to the FDA, the EMA evaluates radiopharmaceuticals for safety, efficacy, quality, and GMP regulation compliance before granting marketing authorization.

Hormones 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.

Trials 52
article thumbnail

Meeting public expectations of diagnostics is the next big test for the NHS

pharmaphorum

Diagnostics was never a Cinderella sector; Britain has the fifth largest in vitro diagnostics (IVD) market in Europe, not gigantic but significant nevertheless. Across the UK, radiology departments are understaffed by around 43%, while only 3% of histopathology departments have enough staff to meet clinical demand.

article thumbnail

Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

The Pharma Data

Additional cases of ILD/pneumonitis have been observed in the post-marketing setting, with fatalities reported. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Across clinical trials (MONARCH 1, MONARCH 2, MONARCH 3), 3.3% had Grade 3 or 4, and 0.4% had fatal outcomes.

HR 52
article thumbnail

Women’s Health Clinical Trials: Clinical Innovations, Opportunities and Considerations

XTalks

Misconceptions and Biases: Despite the known physiologic, metabolic and hormonal differences between men and women, there remains a long-standing misconception that drugs exert the same effects in both men and women. This surge reflects a growing recognition of the market potential in addressing women’s health.